Business
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
PHILADELPHIA, October 24, 2025--Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
About this update from Gsk Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":271,"url":"https://media.zenfs.com/en/business-wire.com/0e2358a4c2a489ed0ed7fd0e19d71262"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oYxzOYP_HW92BF2pJUvpQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0e2358a4c2a489ed0ed7fd0e19d71262","width":480,"height":271}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Significant unmet need for patients requires new and novel treatments1","length":70,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a daratumumab-based triplet2","length":161,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Blenrep is the only anti-BCMA accessible in the community setting where 70% of patients receive care, and with a new streamlined REMS program3","length":142,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Robust clinical development is ongoing to advance Blenrep in earlier lines of treatment, including newly diagnosed patients4","length":124,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":497,"olType":false},{"type":"text","content":"PHILADELPHIA, October 24, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory (IMID) agent.","length":446,"tagName":"p"},{"type":"text","content":"The Blenrep approval is supported by data from the pivotal DREAMM-7 phase III trial. In patients who had two or more prior lines of therapy (3L+), including a PI and an IMID, Blenrep in combination demonstrated a clinically meaningful 51% reduction in the risk of death [HR 0.49, 95% confidence interval (CI): 0.32-0.76] and a tripled median progression-free survival (PFS) of 31.3 months [95% CI: 23.5-NR] versus 10.4 months [95% CI: 7.0-13.4] for a daratumuma...